Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study

  • Masroor, Mirza (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Amit, Jain (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Javid, Jamsheed (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Mir, Rashid (Faculty of Applied Medical Sciences, University of Tabuk) ;
  • Prasant, Y (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Imtiyaz, A (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Mariyam, Z (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Mohan, Anant (Department of Pulmonary Medicine and Sleep Disorder, All India Institute of Medical Sciences) ;
  • Ray, PC (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals) ;
  • Saxena, Alpana (Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals)
  • Published : 2015.12.03


Background: The epidermal growth factor (EGF) plays important roles in non-small cell lung cancer (NSCLC) susceptibility and functional polymorphism in the EGF (+61A/G) gene has been linked to increased risk of NSCLC. This study aimed to evaluate the role of the EGF +61A/G polymorphism in risk of NSCLC adenocarcinoma (ADC) occurrence and survival in an Indian population. Materials and Methods: This casecontrol study included 100 histopathologically confirmed NSCLC (ADC) patients and 100 healthy controls. EGF (A61G) was genotyped by AS-PCR to elucidate putative associations with clinical outcomes. The association of the polymorphism with the survival of NSCLC patients was estimated by Kaplan-Meier curves. Results: It was found that EGF 61AG heterozygous and GG homozygous genotype is significantly associated with increased risk of NSCLC (ADC) occurrence compared to AA genotype, [OR 2.61 (1.31-5.18) and 3.25 (1.31-8.06), RR 1.51(1.15-2.0) and 1.72 (1.08-2.73) and RD 23.2 (6.90-39.5) and 28.53(7.0-50.1) for heterozygous AG (p=0.005) and homozygous GG (p=0.009)]. Patients homozygous for the G allele exhibited a significantly poor overall survival. The median survival time for patients with EGF 61 AA, AG, and GG genotypes was 10.5, 7.4, and 7.1 months (p=0.02), respectively. NSCLC (ADC) patients with GG + AG exhibited 7.3 months median survival compared to the AA genotype (p=0.009). Conclusions: The present study revealed that the EGF A61G genotype may be a novel independent prognostic marker to identify patients at higher risk of occurrence and an unfavourable clinical outcome.


EGF gene (+61A/G) polymorphism;AS-PCR;NSCLC (ADC) patients


  1. Aaronson SA (1991). Growth factors and cancer. Science 1991. 254, 1146-53.
  2. Alberg AJ, Brock MV, Samet JM (2005). Epidemiology of lung cancer: Looking to the future. J Clin Oncol, 23, 3175-85.
  3. Araujo A, Ribeiro R, Azevedo I, et al (2007). Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist, 12, 201-10.
  4. Carpenter G, Cohen S (1990). Epidermal growth factor. J Biol Chem, 265, 7709-12.
  5. Ciardiello F, Tortoa G (2008). EGFR antagonist in cancer treatment. N Engl J Med, 358, 1160-74.
  6. Ciardiello F, Tortoa G (2001). A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 7, 2958-70.
  7. Costa BM, Ferreira P, Costa S, et al (2007). Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res, 13, 2621-6.
  8. Gan HK, Burgess AW, Clayton AHA, et al (2012). Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res, 72, 2924-30.
  9. Goto Y, Ando T, Goto H, et al (2005). No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev, 14, 2454-6.
  10. Goustin AS, Leof AB, Shipley GD (1986). Growth factors and cancer. Cancer Res, 46, 1015-1029.
  11. Harris R, Chung E, Coffey RJ, et al (2003). EGF receptor ligands. Exp Cell Res, 284, 2-13.
  12. Hu-Lieskovan S, Vallbohmer D, Zhang W, et al (2011). EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res, 17, 5161-9.
  13. Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 5, 341-54.
  14. Ichiro Okamoto, Florian Roka, Julia Krogler, et al (2006). The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. Journal of Investigative Dermatology, 126, 2242-6.
  15. Kang H, Choi JE, Lee WK, et al (2007). +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology, 12, 902-5.
  16. Kenneth K. Tanabe, Antoinette Lemoine, et al (2008). Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis, JAMA, 299, 53-60.
  17. Laurence DJ, Gusterson BA (1990). The epidermal growth factor: A review of structural and functional relationships in the normal organism and in cancer cells. Tumor Biol, 11, 229-61.
  18. Lim Y, Kim JW, Song JY, et al (2005). Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett, 374, 157-60.
  19. Li T, Ke-Wei Ren, and Peng-Fei Liu (2012). Meta-analysis of epidermal growth factor polymorphisms and cancer risk: involving 9,779 cases and 15,932 controls. DNA Cell Biol.
  20. Moulder SL, Yakes FM, Muthuswamy SK, et al (2001). Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/ neu (erbB2) overexpressing breast cancer cells in vitro and in vivo. Cancer Res, 61, 8887-95.
  21. Naruke T, Tsuchiya R, Kondo H, et al (1997). Implications of staging in lung cancer. Chest, 112, 242-8.
  22. Salomon DS, Brandt R, Ciardello F, et al (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 19, 183-232.
  23. Shahbazi M, Pravica V, Nasreen N, et al (2002). Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, 359, 397-401.
  24. Spira A, Ettinger DS (2004). Multidisciplinary management of lung cancer. N Engl J Med, 350, 379-92.
  25. Tabernero J, Macarulla T, Ramos FJ, et al (2005). Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol, 16, 1740-8.
  26. Teixeira A, et al (2008). Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res, 14, 3367-71.
  27. Vauleon E, Auger N, Benouaich-Amiel A, JY, Thillet J, Sanson M: The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet, 172, 33-37.
  28. Wu G, Hasenberg T, Magdeburg R, et al (2009). Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg, 33, 124-9.
  29. Ying Piao, Liu Z, Ding Z, et al (2013). EGF +61A>G polymorphism and gastrointestinal cancer risk: a HuGE review and meta-analysis. Gene, 519, 26-33.
  30. Zhang YM, Cao C, Liang K (2010). Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a metaanalysis. Cancer Epidemiol, 34, 150-6.

Cited by

  1. Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study vol.37, pp.8, 2016,
  2. EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilian population pp.1573-4978, 2019,